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bone morphogenetic protein-15 and accumulated
embryo score of infertility patients with diminished
ovarian reserve undergoing in vitro fertilization: a
randomized controlled trial
Huan H Zhang1, Ping Y Xu1, Juan Wu1, Wei W Zou2, Xia M Xu2, Xia Y Cao1 and Lian Z Wei1*Abstract
Objective: To evaluate the effect of dehydroepiandrosterone (DHEA) on infertility patients with diminished ovarian
reserve undergoing in vitro fertilization.
Methods: This is a prospective study. Ninety-five patients with diminished ovarian reserve were included in this study. Of
them, 42 patients were randomly allocated to the DHEA group, who received DHEA 75 mg daily for three consecutive
menstrual cycles prior to IVF cycles, and 53 patients were allocated to the control group, who entered IVF cycles directly.
All patients were treated with the same ovarian stimulation protocol. Follicular fluid samples from both groups were
collected for bone morphogenetic protein-15 (BMP-15) and growth differentiation factor-9 (GDF-9). Fluid from the first
aspirated follicle without any visible blood contamination was carefully collected. In addition, day 3 Blood samples were
collected pre- and post-treatment of DHEA for serum anti-Mullerian hormone (AMH), follicle stimulating hormone (FSH)
and estradiol (E2) in the DHEA group.
Results: The level of BMP-15 in follicular fluid samples from the DHEA group was significantly higher than that of the
control samples (P=.000). Patients after DHEA treatment demonstrated a significantly higher level of AMH and a
significantly lower level of FSH, E2 compared to themselves prior to DHEA therapy (P=.015; P=.036; P=.002; respectively).
Moreover, the accumulated score of embryos was significantly higher in the DHEA group (P=.033).
Conclusions: These observations confirm the beneficial effect of DHEA for infertility patients with diminished ovarian
reserve.
Trial registration: ChiCTR-TRC-14005002
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social life and delayed age of reproductive today, it is com-
mon to find infertility patients with Diminished ovarian re-
serve (DOR). DOR is a progressive decline of ovarian
oocyte quality and quantity, with an elevated basal follicle
stimulating hormone (FSH) level and less antral follicle* Correspondence: weizhaolian_1@126.com
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unless otherwise stated.count. It is reported in 9–24% of in-vitro fertilization (IVF)
cycles [1]. Patients with DOR have high cancellation rate,
low pregnancy rate, and high abortion rate during IVF [2].
Presently Dehydroepiandrosterone (DHEA) is utilized to
improve the outcome of IVF cycles in about one third of re-
productive centers around the world for accumulated sur-
veys have shown the beneficial effect of DHEA on ovarian
reserve. Casson et al. [3] observed the increase level of
IGF-1 after DHEA supplementation. Study by Barad et al.
[4] noted significant increases in oocyte, embryo numbers
and better embryo grades after DHEA treatment throughLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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twenty-five patients with DOR. Subsequently, Barad et al.
[5] got a conclusion that addition of DHEA gave rise to
pregnancy rate meanwhile other reported a significantly
reduction in Miscarriage rate [6].
However, the early reports on DHEA supplement to the
patients with DOR were still controversial because there
was lack of large-scale, well-designed confirmatory studies
[4,7,8]. To further evaluate the effect of DHEA, ovarian re-
serve markers such as AMH, inhibin-B and antral follicle
count were detected and significant changes were observed
by N. Yilmaz et al. [9]. However, a small-sized randomized
double-blinded placebo-controlled trial observed no signifi-
cant changes in serum AMH and FSH levels [10].
Given this, studies should be continued to assess the
utilization of DHEA in patients with DOR undergoing IVF.
There are still no ideal markers predicting the quality of
oocytes and embryos though there are numerous markers
predicting response to ovarian induction. To our know-
ledge, follicular fluid contains many vital cytokines in reac-
tion of oocyte quality. BMP-15, GDF-9, members of the
transforming growth factor-β super family, are known to be
of great importance for follicle growth and female fertility
[11,12]. GDF-9 deficient female mice were blocked at pri-
mary one-layer follicle stage during follicular development
which eventually leads to complete infertility [13]. High
BMP-15 level in follicular fluid has been demonstrated to
associate with high quality oocyte, high cleavage rate and
good morphology embryos [14].
Therefore, to gain further insights on the effect of DHEA,
here in our study, BMP-15, GDF-9 in follicular fluid were
studied to obtain more evidence. The specific aims of the
present study were: 1) To explore the levels of BMP-15 and
GDF-9 in follicular fluid and compare them between the
DHEA group and the control; 2) To confirm whether there
are significant changes in ovarian reserve markers such as
AMH, FSH, E2 after DHEA supplementation in the study




The study recruited patients with primary or secondary
infertility for diminished ovarian reserve at the Assisted
Reproductive Center, The Affiliated Hospital of Anhui
Medical University between March 2013 and May 2014.
Despite there is no established definition of DOR, predict-
ive criteria such as abnormal ovarian reserve tests (day 3
FSH or AMH level) and previous ovarian response number
of oocytes retrieved after a standard-dose ovarian stimula-
tion are two of the most frequent criteria adopted on the
topic today [15]. In this study the criteria for defining DOR
was defined as follow: 1) an elevated day 3 FSH level ≥ 10
mIU/mL or FSH/LH > 3; 2) the number of antral folliclecount less than five; 3) a previous poor ovarian response:
retrieval of fewer than five oocytes or cycle cancellation due
to poor response to ovarian stimulation. A diagnosed with
DOR was reached if they fulfill any of the above three.
Patients were excluded if they had any of the following: 1) a
history of ovarian cystectomy or oophorectomy; 2) a diag-
nosis of endometriosis; 3) a history of DHEA supplementa-
tion or hormonal replacement therapy.
Methods
This prospective study was approved by the Clinical Re-
search Ethics Committee of The First Affiliated Hospital
of Anhui Medical University. Before the trial, every
participant was fully explained about the present study. A
total of 105 patients fulfilled the selection criteria were
recruited in our present study. According to a computer-
generated randomization list by a nurse, 52 patients were
randomly allocated to the DHEA group who received
DHEA 25 mg three times per day for three consecutive
menstrual cycles prior to IVF cycles and 53 patients to the
control group who entered IVF cycles directly. On the first
menstrual cycle and the fourth menstrual cycle, day 3
blood samples were collected for serum AMH, FSH, E2 in
the DHEA group.
Everyone were given a dose of 225 IU human meno-
pausal gonadotropin (HMG, Lizhu, China) combined with
Clomiphene Citrate (CC, Lizhu, China) 100 mg daily from
day 3 of the cycle to induce follicle growth. When at least
one mature follicle of ≥ 18 mm in mean diameter was seen
on ultrasound, a dose of 10,000 IU of Human chorionic
gonadotropin (HCG, Lizhu, China) was administrated
followed by oocyte retrieval 36 hour later.
Clean follicular fluid was aspirated from leading fol-
licle by trans-vaginal ultrasound-guided puncture for
BMP-15 and GDF-9 detection. Fluid samples from the
first aspirated follicle and without any visible blood
contamination were carefully collected. Samples were
centrifuged at 2000 r/min for 15 minutes and stored
at −80°C until to be tested.
Outcome measures
The primary outcome measures were follicular fluid BMP-
15, GDF-9 and serum AMH, FSH, E2. Secondary outcome
measures were the number of oocytes retrieved, MII oo-
cytes, and embryos transferred; the accumulated score of
embryos.
Sample detection
The concentration of BMP-15, GDF-9, AMH were
determined by enzyme-linked immunosorbent assay
(ELISA) [BMP-15: BMP-15 Gen II ELISA, USCN, USA;
GDF-9: GDF-9 Gen II ELISA, USCN, USA; AMH:
AMH Gen II ELISA, ASNL, USA]. FSH, E2 in serum
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(Beckman Coulter).
Embryo grade
On the third day of incubation, embryos were graded from
one to four, based on percent fragmentation and cell
counts: grade 4, equal-sized symmetrical cells with no frag-
mentation; grade 3, equal-sized symmetrical cells with, 10%
fragmentation; grade 2, non-symmetrical blastomeres with
10-50% fragmentation and grade 1, 50% fragmentation [16].
Up to three, best-quality embryos were transferred on day
3 or day 5. Accumulated embryo score was calculated
by summing the score of each embryo produced by each
patient on the third day of development. For example, a
patient with a grade 4 embryo and two grade 3 embryos
would be assigned a score of 10. Patients with cycle
cancellation would be assigned a score of 0.
Statistical analyses
SPSS for Windows, Standard version 17.0 was utilized for
data analysis. Quantitative variables were presented as
mean ± standard deviation (SD) and analyzed by student’s
t-test. Qualitative variables were presented as proportions
and analyzed by χ2 test. For all analysis, the significant was
set at P<.05.
Results
Between March 2013 and May 2014, a total of 147 patients
with primary or secondary infertility for diminished ovarian
reserve were screened at the Assisted Reproductive Center,
The Affiliated Hospital of Anhui Medical University. Of
them, 105 patients were recruited and randomized. Ex-
cluded 10 patients discontinued intervention; there were 42
patients in the DHEA group and 53 in the control. (See in
Figure 1).
Patients enrolled in the DHEA group and the control
group were aged 37.17 (±5.22) and 37.43 (±4.33) years
respectively. As is shown in Table 1, all descriptive pa-
rameters were comparable between the DHEA group
and the control group in terms of age, body mass index
(BMI), duration of infertility, primary or secondary infer-
tility (P=.785, P=.549, P=.756, P=.126 respectively).
Moreover, serum AMH, FSH, E2, the total number of
antral follicle were all matched in this two groups thus
signifying they shared comparable ovarian reserve
(P=.440; P=.421; P=.835; P=.764 respectively).
Characteristics of IVF cycles regarding with the num-
ber of oocytes, MII oocytes, embryos transferred, and
the score of embryos were also analyzed between the
DHEA group (n = 42) and the control group (n = 53).
As is shown in Figure 2, the accumulated score of em-
bryos was significantly higher in patients treated with
DHEA compared to the control group (4.24 ± 3.39 vs.
2.87 ± 2.79, P=.033). However, no significantly changeswere observed in the number of oocytes retrieved, MII
oocytes and embryos transferred (P=.526, P=.289, P=.076
respectively).
After standardized ovarian stimulation, 26 follicular fluid
samples were collected from the DHEA group, with 6 cy-
cles canceled for poor responses and 10 follicular fluid sam-
ples unqualified for visible blood contamination. In the
control group, we sampled 35 samples with 9 cycles can-
celed and 9 unqualified respectively.
Basic characters of the DHEA follicular fluid (FF) group
and the control follicular fluid (FF) group are presented in
Table 2. No significant differences were found in terms of
serum AMH, FSH, E2, and the total number of antral fol-
licle between the two groups (P=.496; P=.406; P=653;
P=.486 respectively). The mean levels of BMP-15 in the
DHEA FF group (n = 26) and the control FF group (n =
35) were 0.81 (±0.25) ng/ml and 0.35 (±0.23) ng/ml respect-
ively. And a statistically significant difference was found
between the two FF groups (P=.000). No significant differ-
ence was detected in the level of GDF-9 in the DHEA FF
group compared to the control (7.91 ± 3.77 vs. 6.82 ± 2.46,
P=.203).
A comparison of ovarian reserve markers was made be-
tween before and after treatment in the 42 patients treated
with DHEA. The mean duration of DHEA supplementa-
tion was 83.67 ± 6.45 days. The levels of DHEA-S and tes-
tosterone were significantly higher after treatment (1.24 ±
0.74 μg/mL vs. 5.50 ± 3.48 μg/mL, p=.000; 0.74 ± 0.41
nmol/L vs. 2.25 ± 1.28 nmol/L, p=.000). And there was a
significant increase of AMH (1.01 ± 0.77 ng/ml vs. 1.29 ±
1.09 ng/ml, P=.015) and a significant decrease of FSH
(11.68 ± 6.62 IU/L vs. 9.45 ± 5.09 IU/L, P=.036) and E2
(186.58 ± 142.19 pg/ml vs. 110.79 ± 68.28 pg/ml, P=.002)
after about 12 weeks of DHEA supplementation. However
no significant change was found in the count of antral fol-
licle (2.95 ± 1.38 vs. 3.21 ± 1.22; P=.054). (See in Table 3).
In these 42 patients received DHEA treatment, eight
patients conceived after the IVF cycles, with a pregnancy
rate of 19.05%. In the control, seven patients conceived
with a pregnancy rate of 13.21%. And there was no sig-
nificant difference in pregnancy rate between them
(P=.816).
During this trial, no major adverse effects were reported.
Only one patient complained of dizziness and three pa-
tients complained of acne.Discussion
This is the first report concerning the relationship between
the DHEA supplementation for patients with DOR and the
level of BMP-15 and GDF-9 in follicular fluid. The present
study found a significantly higher level of BMP-15 in fol-
licular fluid of patients treated with DHEA prior to IVF cy-
cles than patients entered IVF cycles directly.
Figure 1 Consort 2010 flow diagram.
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follicular fluid is associated with high quality oocyte and
good morphology embryos [11]. Moreover, poor re-
sponders with a high level of BMP-15 in follicular fluid
demonstrated higher implantation rate and pregnancy
rate than those in the low BMP-15 group [17]. Here in
our study, the higher level of BMP-15 observed in
DHEA treated group predicted better ovarian reserve
and outcome of IVF cycles.
Additionally, some other ovarian reserve markers
such as serum AMH, FSH, E2 and the count of antral
follicle were measured before and after the supplemen-
tation of DHEA in this article. There was a significant
higher level of AMH, a significantly lower level of FSH
and E2 after about 12 weeks treatment of DHEA.However, no significant change was observed in the
count of antral follicle in our study. Research also noted
that DHEA supplementation improved serum AMH, in-
hibin B and antral follicle count in patients with DOR.
Serum level of AMH increases in parallel with length of
DHEA supplementation [18]. Subsequently, other study
observed a significant increase in AFC and ovarian vol-
ume but no significant differences were found in the
levels of AMH and FSH [10].
Furthermore, main IVF cycle characteristics were
compared between the two groups in our study. The ac-
cumulated score of embryos were significantly higher in
patients treated with DHEA. Thus signified a better
quality of embryos and strengthened the observations in
ovarian reserve markers above. And there was a trend
Table 1 Basic characters of patients in the DHEA group and the control group
Paremeters The DHEA group The control group P-value
n = 42 n = 53
Age (years) 37.17 ± 5.22 37.43 ± 4.33 .785
BMI (kg/m2) 22.13 ± 2.92 22.46 ± 2.42 .549
Duration of infertility(years) 6.64 ± 4.54 6.34 ± 4.85 .756
Primary infertility (%) 42.86 % 26.42% .126
Secondary infertility (%) 57.14 % 73.58%
AMH (ng/ml) 1.01 ± 0.77 1.12 ± 0.84 .440
FSH(mIU/mL) 11.68 ± 6.62 10.81 ± 2.41 .421
Estradiol (pg/ml) 186.58 ± 142.19 193.06 ± 156.16 .835
Antral follicle count 2.95 ± 1.38 3.04 ± 1.38 .764
Data are presented as mean ± SD (standard deviation) or percentage as appropriate. BMI: body mass index. P<.05 was considered as statistically significant.
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and embryos transferred in the presence of DHEA,
though this effect was not statistically significant.
In agreement with our study, Barad et al. [4] reported that
DHEA treatment gave rise to a significant increase in oo-
cyte, embryo numbers and better embryo grades through
paired analysis of before and after IVF parameters of twenty
five patients with DOR. In a late follow up, the first pro-
spectively randomized clinical trial was published which
suggested that addition of DHEA increased embryo quality
and live birth rates in patients with DOR [16]. However, this
paper has not accepted well as for its low number of 33Figure 2 Comparison of IVF cycle outcomes between the DHEA groupsubjects with 17 in the DHEA group and 16 in the control.
Subsequently in 2012, a study enrolled 133 DOR patients
with 67 used DHEA and 63 without DHEA was reported. It
demonstrated that peak E2, endometrial thickness, number
of oocytes retrieved, number of embryos transferred in the
study group were significantly higher than the control [19].
All of these observations raise a question, what may prob-
ably be the mechanism by which DHEA exert its effect on
ovarian reserve? Recent data mostly focus on androgens re-
ceptor (AR), hold the opinion that androgens primarily
affect granulose cells (GC) with ligand-activated AR [20].
AR-knockout (ARKO) female mice model revealed lowand the control.
Table 2 The outcome comparison between the DHEA FF group versus the control FF group
Paremeters The DHEA FF group The control FF group P-value
n = 26 n = 35
Age (years) 36.58 ± 5.95 37.83 ± 4.28 .367
BMI (kg/m2) 22.49 ± 3.10 22.66 ± 2.39 .813
Duration of infertility(years) 7.04 ± 4.99 6.60 ± 5.01 .736
Primary infertility (%) 42.31% 25.71% .270
Secondary infertility (%) 57.69% 74.29%
AMH (ng/ml) 1.00 ± 0.81 1.19 ± 0.94 .496
FSH (mIU/mL) 11.78 ± 4.92 10.70 ± 2.40 .406
Estradiol (pg/ml) 174.47 ± 122.85 190.45 ± 145.87 .653
Antral follicle count 3.73 ± 1.04 3.51 ± 1.29 .486
BMP-15 (ng/ml) 0.81 ± 0.25 0.35 ± 0.23 .000
GDF-9 (ng/ml) 7.91 ± 3.77 6.82 ± 2.46 .203
Data are presented as mean ± SD (standard deviation) or percentage as appropriate. FF: Follicular fluid. P<.05 was considered as statistically significant.
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cantly higher rates of GC and follicles apoptosis, poor re-
sponses to ovarian induction with gonadotropins [21].
ARKO model demonstrated that ARs are crucial important
for normal follicle genesis and development. Higher con-
centration of AR mRNA and AR protein were detected in
pre-antral and early antral follicles which suggested the
peak effect of androgens [22].
To gain further light into the effect of androgens, pre-
ovulatory granulose cells in follicular fluid were collected
from patients undergoing IVF treatment, and cultured with
the absence or presence of a low concentration of DHEA-S
by ElBeltagy [23]. Increased expression of AR was detected
after treatment of DHEAS compared to cells absence of
DHEAS. This study explained that DHEAS may exert its
effect on follicle development through up-regulating AR.
Human GC and follicular fluid from small antral folli-
cles were obtained from ovaries surgically removed for fer-
tility preservation by Nielsen et al. [24], who noted the
expression of AR mRNA in GC and concentrations of an-







AMH (ng/ml) 1.01 ± 0.77 1.29 ± 1.09 .015
FSH (mIU/mL) 11.68 ± 6.62 9.45 ± 5.09 .036
Estradiol (pg/ml) 186.58 ± 142.19 110.79 ± 68.28 .002
DHEA-S (μg/mL) 1.24 ± 0.74 5.50 ± 3.48 .000
Testosterone
(nmol/L)
0.74 ± 0.41 2.25 ± 1.28 .000
Antral follicle
count
2.95 ± 1.38 3.21 ± 1.22 .054
Data are presented as mean ± SD (standard deviation). P<.05 was considered
as statistically significant.expression of FSH receptor mRNA. Moreover, the expres-
sion of AR mRNA also showed a positive association with
AMH receptor in their research. This indicated that
proper androgens may potentially increase FSH receptor
and AMH receptor.
In one word, androgens appear most modulate FSH re-
sponsibility through AR at stages of pre-antral and antral
follicles [25]. Addition of DHEA could increase FSH recep-
tor at early stages of folliculogenesis. Therefore DHEA could
beneficially affect follicle recruitment.
Additionally, the secondary effect of DHEA on estrogen
receptor could not be neglected. According to the two cell/
two gonadotrophin theory, androgens play an essential role
in ensuring adequate follicular steroidogenesis in human.
DHEA is a crucial precursor steroid to human sex steroid
synthesis and is converted to androgens or estrogens. Estro-
gens promote ovarian follicular growth and granulosa cell
proliferation [26].
DHEA promotes the growth of small follicles, especially
preantral and early-antral follicles. Since AMH is secreted
by them, it is not difficult to understand the increase of
AMH. However, the increase of AFC did not reach statisti-
cally difference. Why? Pre-antral and early-antral follicles
could not be seen on ultrasound. We can only monitor the
count of antral follicles, not the total number of pre-antral ,
early-antral and antral follicles. And AMH may reflect not
only the quantity but also the quality of small follicles. The
increase of AMH may be caused by the increased small fol-
licles or the improved follicle quality or the both.
Here in our study, a significantly higher level of BMP-
15 in follicular fluid of patients treated with DHEA was
also observed. We speculated that DHEA may probably
affect the level of BMP-15 in circulation via androgen
receptors (AR). It has been demonstrated that multiple
regulatory factors such as tyrosine kinases by Ligand
(KITL), BMP-15, GDF-9 and so on are under the
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between oocytes and granulose cells.
It has been confirmed that both GDF-9 and BMP-15
stimulate FSH receptor and increase the sensitivity to FSH
but only BMP-15 was observed to up-regulate AMH ex-
pression at mRNA and protein level in GC [28]. What is
more, recent research indicated that high level of FSH sup-
pressed the expression of BMP-15, and there is a negatively
correlation between them [29]. It may be inferred that here
exist a feedback loop between BMP-15 and FSH. Therefore
in present study, it is reasonable for us to assume that
DHEA supplementation may potentially enhance FSH sen-
sitivity and increase the expression of BMP-15 in follicular
fluid. However, no significant difference was found in the
level of GDF-9. It is likely that there exists some difference
in the paths of regulating oocyte growth between BMP-15
and GDF-9 though they make function in a synergistic
way. And the relationships between BMP-15 and andro-
gens need further research to clarify.
Strengths and limitations
Strengths of this study were: 1) It was the first study
concerning the relationship between DHEA supplementa-
tion and BMP-15, GDF-9 in follicular fluid. 2) Follicular
fluid samples were collected distinguished serum samples
in former studies assessed the effect of DHEA; 3) This
research was conducted in a prospective way which en-
sured the consistency and comparability of the study group
and the control.
Limitations of the study: It is not a placebo-controlled
trial for patients with DOR were eager to receive treatment
other than take placebo pills because of limited time to
fertility.
Conclusions
In summary, DHEA supplementation improves follicular
fluid BMP-15, serum AMH and accumulated embryo score
of patients with DOR. Herein, addition of DHEA prior to
IVF-cycles is an effective option for patients with DOR.
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